2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2016 Symposium: Save the Date!


Our 12th Annual Moores Cancer Center Industry/Academia Translational Oncology Symposium will be held on Thursday February 25, 2016.



2015 Symposium Featured Talks


Please enjoy the featured talks below from our recent symposium. Thank you!

Please note: These videos are for private viewing only. Any unintended use of the videos without consent is prohibited.

Symposium Organizer Welcome


Ida Deichaite, PhD
UC San Diego Moores Cancer Center




Moores Cancer Center Welcome


Scott Lippman, MD
UC San Diego Moores Cancer Center




Dean, School of Medicine Welcome


David Brenner, MD
UC San Diego School of Medicine




Chancellor Welcome


Pradeep Khosla, PhD
UC San Diego




Finding the Money to Fund Translational Research


Rep. Scott Peters, Congressman
Bob Klein, Klein Financial Corporation



National Entrepreneurs Month Presented to the Roth Family


Presented by Rep. Scott Peters, Congressman




Duane Roth Award


Presented by Rep. Scott Peters, Congressman
Awarded to Brian Druker, MD, OHSU Knight Cancer Institute



Keynote Presentation: Imatinib as a Paradigm of Molecularly Targeted Cancer Therapies


Brian Druker, MD
OHSU Knight Cancer Institute


Drugging the Undrugable: KRAS


D. Lynn Kirkpatrick, PhD
PHusis Therapeutics




ePatients on the Front Lines: Precision Medicine, the FDA, and Me


Janet Freeman-Daily, MS, ENG
Patient Advocacy



Keynote Presentation: Cancer Genomics: Turning Discovery into Translation


Elaine Mardis, PhD
The Genome Institute
Washington University School of Medicine



Advancing the Utility of Clinic Sequencing for MDS


Rafael Bejar, MD, PhD
UC San Diego Moores Cancer Center



A More Beautiful Question


Brad Perkins, MD
Human Longevity




A novel bispecific antibody targeting EGFR and cMet with multiple mechanisms of action


Mark Anderson, PhD
Janssen Pharmaceuticals


Napoleon in Rags and the Language that he Used: the New World of Immunotherapy in Head and Neck Cancer


Ezra Cohen, MD
UC San Diego Moores Cancer Center


Melanoma Patients Path: Translations to the Clinic


Gregory Daniels, MD
UC San Diego Moores Cancer Center



Targeting PI3Kgamma and BTK to suppress tumor-associated inflammation


Judith Varner, PhD
UC San Diego Moores Cancer Center



CIRM 2.0. Building a better stem cell agency


C. Randal Mills
California Institute for Regenerative Medicine



Patient's Perspective


Theresa Blanda
Patient

Catriona Jamieson, MD, PhD
UC San Diego Moores Cancer Center



2015 Symposium


Our 11th Annual Moores Cancer Center Industry/Academia Translational Oncology Symposium took place on Thursday February 19, 2015. We thank all of our speakers and attendees for a successful event! We look forward to the collaborations that will blossom and future symposia.

February 22, 2015

CIRM's Klein proposes $100B biomed program: Bob Klein describes his vision of how to increase biomedical funding to hasten discovery and commercialization of disease treatments. He spoke Thursday, Feb. 19, at the annual UCSD Moores Cancer Center symposium.
» San Diego Union Tribune article


February 21, 2015

Fighting patient, fighting doctor: : Patient Theresa Blanda speaks about her experience battling cancer with the help of Moores Cancer Center Investigator Dr. Catriona Jamieson, at the 11th annual Industry/Academia Translational Oncology Symposium.
» San Diego Union Tribune article


February 19, 2015

Katherine Connor from the San Diego Daily Transcript reports on the new funding paradigm needed for scientific research: Some of the nation’s top oncology researchers and private companies in the cancer space met at the University of California, San Diego Moores Cancer Center Thursday for the 11th annual Industry/Academic Translational Oncology Symposium.
» San Diego Daily Transcript article


February 13, 2015

The Union-Tribune published an opinion editorial by Moores Cancer Center Director of Industry Relations Ida Deichaite, PhD, entitled "Finding Ways to create cancer-killing swords". The op-ed features the upcoming 11th Annual Moores Cancer Center Industry/Academia Translational Oncology Symposium on February 19, and the ongoing collaborations at MCC.
» Union Tribune Op-ed



Keynote Speaker
Cancer Genomics: Turning Discovery into Translation

Elaine Mardis, PhD

The Genome Institute
Washington University School of Medicine

Keynote Speaker
Imatinib as a Paradigm of Molecularly Targeted Cancer Therapies

Brian Druker, MD

OHSU Knight Cancer Institute


Duane Roth Award

Presented by Congressman Scott Peters

Congressman Scott Peters serves California'a 52nd Congressional District, which includes the cities of Coronado, Poway, and most of northern San Diego. First elected in 2012, he currently serves on the House committees on Armed Services & on Science, Space, & Technology Committee.


A novel bispecific antibody targeting EGFR and cMet with multiple mechanisms of action

Mark Anderson, PhD

Scientific Director
Janssen Pharmaceuticals

Advancing the Utility of Clinic Sequencing for MDS

Rafael Bejar, MD, PhD

Moores Cancer Center

Welcome and Overview

David Brenner, MD

UCSD School of Medicine

Reversing Drug Resistance in Cancer Stemness

David Cheresh, PhD

Moores Cancer Center

Napoleon in Rags and the Language that he Used: the New World of Immunotherapy in Head and Neck Cancer

Ezra Cohen, MD

Moores Cancer Center

Targeting tumor-associated inflammation in cancer

Lisa Coussens, PhD

OHSU Knight Cancer Institute

Melanoma Patients Path: Translations to the Clinic

Gregory Daniels, MD

Moores Cancer Center

Combining VEGF inhibitors with strategies to manipulate the immune system in cancer

Napoleone Ferrara, MD

Moores Cancer Center

ePatients on the Front Lines: Precision Medicine, the FDA, and Me

Janet Freeman-Daily

Patient Advocacy

The Cancer Cell Map Initiative (CCMI) - Mapping the hallmark networks of cancer

Trey Ideker, PhD

UC San Diego

Bringing Btk inhibition forward

Danelle James, MD, MAS

Head of Oncology
Pharmacyclics

Preclinical and Clinical Cancer Stem Cell Detection and Elimination

Catriona Jamieson, MD, PhD

Moores Cancer Center

Welcome and Overview

Pradeep Khosla, PhD

UC San Diego

Drugging the Undrugable: KRAS

D. Lynn Kirkpatrick, PhD

President and Chief Executive Officer
PHusis Therapeutics Inc.

Finding the Money to Fund Translational Research

Bob Klein

President, Founder, and CEO
Klein Financial Corporation

Welcome and Overview

Scott Lippman, MD

Moores Cancer Center

CIRM 2.0. Building a better stem cell agency

C. Randal Mills, PhD

President and Chief Executive Officer
California Institute for Regenerative Medicine

A More Beautiful Question

Brad Perkins, MD

Chief Medical Officer
Human Longevity, Inc.

Engineering the immune system with chimeric antigen receptors to eradicate cancer

Margo Roberts, PhD

Chief Scientific Officer
Kite Pharma

Development of Next Generation Angiogenesis Inhibitors

Charles Theuer, MD, PhD

Chief Executive Officer
TRACON Pharmaceuticals

Targeting PI3Kgamma and BTK to suppress tumor-associated inflammation

Judith Varner, PhD

Moores Cancer Center




“When you go to an international cancer symposium with 30,000 people, it’s hard to get to the real champion of a project and get their individualized attention. The Moores Cancer Center Translational Oncology Symposium is much more intimate. Industry and academia are on equal footing and there are plenty of opportunities for informal discussions when a lot of synergies develop and collaborations begin or grow.”

- Catriona Jamieson, Ph.D., M.D.,
Director of Stem Cell Research at Moores Cancer Center


The MCC Translational Oncology Symposium is designed as an international forum to foster introductions, stimulate productive conversations among people of complementary interests and galvanize collaborations that will have a profound impact on patient health. It’s a melding of minds in the field of cancer research. Represented will be many of the different skill sets needed to bring a new drug to market – from the lab, through the commercialization process to the patient’s bedside.

Hear from global thought leaders in some of the most promising frontiers of research and treatment, including immunotherapy, antibodies and personalized medicine. Meet top academic researchers, renowned clinicians, and top business development professionals and scientists from the world’s leading pharmaceutical companies and innovative biotechnology companies working in oncology.

In a global environment of budget cuts, including investment in scientific research, industry/academia collaborations are crucial to leverage resources and expertise. In its first ten years, the MCC Translational Oncology Symposium has shown great success in forging collaborations that are speeding drug development times and saving lives:

  • Collaboration between Pfizer and MCC led to a multisite international clinical trial of a sonic hedgehog inhibitor. One patient who was told she had just months to live is alive three years later and has undergone a bone marrow transplant after participating in the trial.
  • Collaboration between San Diego-based TargeGen, MCC and Stanford University, which sped the development of a JAK2 inhibitor and led to the acquisition of TargeGen.




Symposium Organizers and Chairs


Symposium Organizers:

Scott Lippman, MD
Director
UCSD Moores Cancer Center


Symposium Chair:

David Cheresh, PhD
Associate Director for Innovation and Industry Alliances,
Distinguished Professor of Pathology
UCSD Moores Cancer Center



Ida Deichaite, PhD
Director, Industry Relations
UCSD Moores Cancer Center


Symposium Co-Chair:

Catriona Jamieson, MD, PhD
Associate Professor of Medicine,
Chief, Division of Regenerative Medicine
Deputy Director, Sanford Stem Cell Clinical Center
Director, Moores Cancer Center Stem Cell Research Program UCSD Moores Cancer Center










We Thank Our Sponsors: